Replies to post #326822 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Regardless of authors, drug and company, a pre-clinical paper rarely does anything for share price and especially not in pre-print prior to passing peer review.

Having said that its an interesting paper and one reason Anavex is planning a trial in FXS.